BRONCHIECTASIS

INS1007-301


ASPEN Bronchiectasis Study

Study Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects With Non-Cystic Fibrosis Bronchiectasis

Study duration

13 months

Number of CLINIC VISITS

8 clinic visits

NUMBER OF PHONE CALLS

4 phone calls

Main entry criteria
  • 18 years of age or over
  • Confirmed diagnosis of bronchiectasis
  • Had at least 2 bronchiectasis exacerbations requiring treatment with antibiotics in the past 12 months
  • Able to produce sputum spontaneously

There are additional eligibility requirements to enrol in this study. Our Study Doctor will review the study requirements and discuss your eligibility with you either over the telephone or at your first clinic visit.

Assessments
  • Breathing tests
  • Blood pressure and pulse
  • Questionnaires
  • ECGs
  • Blood tests
  • Sputum collection

You will receive all study-related procedures, medications, and laboratory services at no cost. In addition, you will be reimbursed $50 per visit for your time and travel.

Loading...